AX-2026-043651 · Pramlintide · WXT lot WXT-2603-D6459

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	98.21	% area	≥ 97.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.79	% area	≤ 2.5	PASS
Largest single impurity	RP-HPLC — des-Lys1 (−128 Da)	1.21	% area	≤ 1.00	FAIL
Identity — theoretical monoisotopic mass	calculated from molecular formula	3947.1064	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	3947.1253	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+4.8	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	89.92	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	88.31	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	1.15	mg	1 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	1.016	mg	1 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	101.6	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	4.97	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.84	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.27	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.95	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	13.11	min	13.09 ± 0.35 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.13	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	46,241	—	≥ 20,000	PASS
Resolution to nearest impurity	vs C-terminal free acid (+1 Da)	1.08	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 46,241, and skew follows the reported asymmetry factor of 1.13. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.21 % impurity against a 98.21 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Pramlintide — main peak	13.11	4,773,310	98.21	—
2	des-Lys1 (−128 Da)	12.63	58,810	1.21	-128.095
3	open-chain (reduced disulfide, +2 Da)	12.25	17,983	0.37	+2.016
4	C-terminal free acid (+1 Da)	13.38	5,346	0.11	+0.984
5	pramlintide dimer	15.85	4,860	0.10	+3945.091
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 3947.1064 Da, computed from C171H267N51O53S2. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 3947.1253 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
6+	658.8583	658.8615	0.0032	7.7
5+	790.4286	790.4323	0.0037	57.6
4+	987.7839	987.7886	0.0047	100.0
3+	1316.7094	1316.7157	0.0063	56.3
2+	1974.5605	1974.5699	0.0094	8.1

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.97
Counter-ion (acetate)	ion chromatography	4.84
Residual solvent + inorganic residue	estimated	0.27
Total peptide content	by difference	89.92
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.5	98.21	divergence +0.43 pp vs batch median
Total impurities (% area)	1.50	1.79
Largest single impurity (% area)	0.58	1.21
Water (%)	not stated	4.97
Counter-ion (%)	6.8	4.84
Peptide content (%w/w)	89.1	89.92
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Domestic warehouse despatch → submitter (2–8 °C, 25 d) → laboratory (courier, cold pack, 5 d) → assay.
Assay date: 22 Sep 2026
Submitted to the index: 17 Oct 2026
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

mass_defect17 Oct 2026

Mass, retention and impurity profile all agree on this record. Three independent constraints pointing the same way is the strongest identity evidence the index publishes.

round_numbers17 Oct 2026

The declared figure for WXT-2603-D6459 and the independent median differ by less than the inter-lab limits of agreement. That is the comparison that matters and the rounding does not change it.

dispute_log17 Oct 2026

Suppliers asked about a rounded declaration in this index have supplied the underlying integration without argument. That response is itself informative and it is the outcome in every case on file.

Section 7

Related records

Same batch — lot WXT-2603-D6459 n=8

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043649	WXT-2603-D6459	Nordanalyt	2026-Q3	98.18	4.43	98.3	Buyer-sourced	1	MARGINAL
AX-2026-043650	WXT-2603-D6459	Janoshik	2026-Q3	98.07	4.96	100.9	Buyer-sourced	1	MARGINAL
AX-2026-043652	WXT-2603-D6459	Janoshik	2026-Q3	98.08	4.01	—	Buyer-sourced	1	MARGINAL
AX-2026-043653	WXT-2603-D6459	Nordanalyt	2026-Q3	98.23	4.73	96.1	Buyer-sourced	1	MARGINAL
AX-2026-043654	WXT-2603-D6459	Janoshik	2026-Q3	97.90	4.52	105.7	Buyer-sourced	1	MARGINAL
AX-2026-043655	WXT-2603-D6459	PeptideMeter	2026-Q3	98.00	4.87	98.6	Buyer-sourced	1	MARGINAL
AX-2026-043656	WXT-2603-D6459	Janoshik	2026-Q3	98.05	5.20	—	Buyer-sourced	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Pramlintide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043653	WXT	WXT-2603-D6459	Nordanalyt	2026-Q3	98.23	4.73	96.1	Buyer-sourced	1	MARGINAL
AX-2026-043650	WXT	WXT-2603-D6459	Janoshik	2026-Q3	98.07	4.96	100.9	Buyer-sourced	1	MARGINAL
AX-2026-043656	WXT	WXT-2603-D6459	Janoshik	2026-Q3	98.05	5.20	—	Buyer-sourced	1	MARGINAL
AX-2026-043649	WXT	WXT-2603-D6459	Nordanalyt	2026-Q3	98.18	4.43	98.3	Buyer-sourced	1	MARGINAL
AX-2026-043654	WXT	WXT-2603-D6459	Janoshik	2026-Q3	97.90	4.52	105.7	Buyer-sourced	1	MARGINAL
AX-2026-043655	WXT	WXT-2603-D6459	PeptideMeter	2026-Q3	98.00	4.87	98.6	Buyer-sourced	1	MARGINAL
AX-2026-043652	WXT	WXT-2603-D6459	Janoshik	2026-Q3	98.08	4.01	—	Buyer-sourced	1	MARGINAL
AX-2026-041561	QSC	QSC-2511-T6310	VendorInvestigate	2026-Q1	99.10	5.22	—	Buyer-sourced	0	PASS

Other recent WXT records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043531	Leuprolide	WXT-2604-K4483	Medutest	2026-Q3	99.00	5.03	—	Buyer-sourced	0	PASS
AX-2026-043561	Semaglutide	WXT-2604-C5135	Janoshik	2026-Q3	96.96	4.22	91.3	Buyer-sourced	0	FAIL
AX-2026-043627	L-Glutathione (reduced)	WXT-2605-B5720	Janoshik	2026-Q3	97.96	6.08	92.3	Buyer-sourced	1	FAIL
AX-2026-043564	Semaglutide	WXT-2604-C5135	Janoshik	2026-Q3	97.15	4.44	104.7	Buyer-sourced	0	PASS
AX-2026-043533	Leuprolide	WXT-2604-K4483	PeptideMeter	2026-Q3	99.89	4.94	—	Supplier-supplied	0	PASS
AX-2026-043624	L-Glutathione (reduced)	WXT-2605-B5720	Nordanalyt	2026-Q3	98.18	6.95	105.3	Buyer-sourced	2	FAIL
AX-2026-043556	Semaglutide	WXT-2604-C5135	PeptideMeter	2026-Q3	97.56	4.35	89.6	Buyer-sourced	1	MARGINAL
AX-2026-043539	Leuprolide	WXT-2604-K4483	Nordanalyt	2026-Q3	98.78	5.31	—	Buyer-sourced	0	PASS